Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
APP’s Better Half? Soluble Fragment Activates Protective Genes
26 September 2010. As amyloid precursor protein (APP) gets sliced and diced, the fragments coming off the β-secretase tend to steal the show—in particular, the C-terminal piece that contains the amyloid-β peptide found in the hallmark plaques of Alzheimer disease brains. But what about the other half? In this week’s PNAS Early Edition, scientists propose an intriguing new role for the soluble, secreted N-terminal part, otherwise known as sAPPβ. Hui Zheng, Baylor College of Medicine, Houston, Texas, and colleagues report that sAPPβ acts as a transcriptional enhancer of sorts, with transthyretin (TTR) and Klotho as downstream targets. As these genes help cells withstand AD pathology and aging, respectively, the data suggest a potential self-preservation mechanism where each cut of APP by β-secretase not only helps unleash Aβ, but also a soluble APP fragment to upregulate factors counteracting its toxicity. However, while sAPPβ alone was able to recapitulate APP-mediated transcriptional regulation of TTR and Klotho, the fragment was not totally heroic—it could not stand in for its full-length precursor in critical developmental functions. “Soluble APPβ performs, on its own, an important biological function, but this accounts for only part of the overall activity of APP,” said Thomas Südhof, Stanford University, Palo Alto, California, who co-led the research with Zheng. The data could fuel efforts to identify receptors and other signaling molecules that mediate sAPPβ’s protective effects, which could expand possibilities for AD therapeutic approaches.

Zheng and other investigators have established that APP-deficient mice show cognitive and motor weaknesses, but otherwise live full, fertile lives (Zheng et al., 1995; Dawson et al., 1999). On the other hand, double-knockout mice that lack both APP and its family member APLP2 die soon after birth (see Li et al., 1996 and ARF related news story, and von Koch et al., 1997) with severe defects in their neuromuscular synapses (Wang et al., 2005). Similarly, worms deficient in APL-1, the only APP-related gene in C. elegans, do not survive. However, those worms live if just the APL-1 ectodomain is expressed in their neurons (Hornsten et al., 2007), suggesting that this soluble fragment can mediate the essential functions of full-length APL-1.

First authors Hongmei Li and Baiping Wang did the analogous experiment in mice, asking whether sAPPβ is itself functional—in other words, could it rescue the double knockout of APP and APLP2? To address the issue, the researchers generated mice with an APP knock-in (sAPPβ ki) allele that exclusively expresses FLAG-tagged sAPPβ protein, but no full-length APP. They bred those animals onto an APLP2-null background, and crossed double heterozygotes (sAPPβ ki/- APLP2+/-) with each other, in hopes of generating APP/APLP2-null mice with varying sAPPβ gene dosage. Though pups genotyped at birth showed the expected Mendelian gene distribution, exceedingly few survived to weaning age, indicating that sAPPβ fails to rescue the postnatal lethality of APP/APLP2 double-knockout mice.

What about other possible roles for sAPPβ? These emerged after the authors looked more closely at APP’s role in transcription. Prior studies suggest that APP acts through yet another fragment—its intracellular domain also known as AICD—to regulate gene transcription (Cao and Südhof, 2001 and ARF related news story; Cao and Südhof, 2004), and have proposed a good number of downstream targets, many of them “questioned or disputed,” the authors write.

To explore whether the sAPPβ fragment might also play a role in gene transcription, Li, Wang, and colleagues created neuronal-specific APP/APLP2 double-conditional knockout (dcKO) mice. They extracted hippocampal tissue for microarray analysis, looking for genes expressed at different levels in these animals compared with APLP2-null controls. The analysis identified some 30 genes, most of which were downregulated in the APP/APLP2 dcKO samples. The scientists focused on two, TTR and Klotho, that were reported to be upregulated in the brains of APP-overexpressing animals (Stein et al., 2002; Wu et al., 2006). Using quantitative RT-PCR, the authors confirmed that TTR and Klotho expression were elevated in APP-overexpressing hippocampal tissue from Tg2576 mice, and decreased in APP/APLP2 dcKO samples, relative to APLP2-null controls. Curiously, however, they found no downregulation of TTR or Klotho in sAPPβ ki+/- APLP2-null mice. This indicates that sAPPβ was sufficient to support expression of these genes.

“Our findings raise the possibility that impaired APP extracellular processing could contribute to AD pathogenesis during aging through misregulation of TTR and Klotho,” Zheng told ARF via e-mail. TTR has been shown to sequester and degrade Aβ (Costa et al., 2008), as well as protect against AD pathology in mice (Buxbaum et al., 2008 and ARF related news story). Klotho increases resistance to oxidative stress (Yamamoto et al., 2005) and seems to act as an anti-aging factor, based on studies showing that mice lacking Klotho age prematurely and develop cognitive impairment (Kuro-o et al., 1997). Moreover, Klotho expression drops off with age in rhesus monkeys (Duce et al., 2008).

“It would be interesting to see to what extent the upregulation of Klotho and TTR by sAPPβ persists with aging,” said Suzanne Guenette, Massachusetts General Hospital, Charlestown. “Furthermore, identification of the receptors for sAPPβ involved in this protective effect might be useful as therapeutic targets for AD, particularly since TTR is known to be downregulated in AD CSF” (Serot et al., 1997; Merched et al., 1998).

In Südhof’s view, “what’s important here is not which genes are regulated, but that sAPPβ regulates them. This means sAPPβ must bind to something, either a receptor or other signaling molecules. There must be a biological function of sAPPβ that is independent of the function of APP that requires its C-terminus.”

Moreover, the current study reports that the sAPPβ produced by sAPPβ ki/ki mice was highly stable, as judged by the absence of cleavage products in cell lysates and conditioned media probed with N-terminal anti-APP and C-terminal anti-FLAG antibodies. This appeared at odds with a report showing that sAPPβ gets further cleaved to make an N-terminal fragment that binds death receptor 6 (DR6) and mediates axon pruning and neuronal cell death during development (Nikolaev et al., 2009 and ARF related news story). Whether the FLAG tag interferes with degradation is not clear. Also, “it’s possible that the cleavage occurs and is quickly degraded, or that it happens under pathological conditions,” Südhof said. “But in the experiments we performed in the sAPPβ ki/ki mice, this was not a major pathway for sAPPβ clearance.”—Esther Landhuis.

Reference:
Li H, Wang B, Wang Z, Guo Q, Tabuchi K, Hammer RE, Südhof TC, Zheng H. Soluble amyloid precursor protein (APP) regulates transthyretin and Klotho gene expression without rescuing the essential function of APP. PNAS Early Edition. Sept 2010. Abstract

 
Comments on News and Primary Papers
  Primary Papers: Soluble amyloid precursor protein (APP) regulates transthyretin and Klotho gene expression without rescuing the essential function of APP.

Comment by:  Makoto Kuro-o
Submitted 26 September 2010  |  Permalink Posted 26 September 2010

The link between APP and Klotho is novel and very interesting. APP and Klotho share several common features: 1) They are single-pass transmembrane proteins with short intracellular domains; 2) they are substrates of α-, β-, and γ-secretases; 3) their extracellular domains are secreted and function as humoral factors.

Secreted Klotho has an activity that alleviates oxidative stress (Yamamoto et al., 2005) were reported to suffer cognitive impairment due to increased apoptosis of hippocampal neurons, which was rescued by administration of antioxidant (vitamin E) (Nagai et al., 2003).

Activation of BACE generates both Aβ and APPsβ. It will also facilitate secretion of Klotho. Thus, the ability of AAPsβ to increase Klotho expression may counteract harmful effects of Aβ by increasing secreted Klotho under the condition where BACE is activated. A major issue highlighted by this paper is a potential role of APP in the regulation of Klotho expression, the decline of which is known to...  Read more


  Primary Papers: Soluble amyloid precursor protein (APP) regulates transthyretin and Klotho gene expression without rescuing the essential function of APP.

Comment by:  Virgil Muresan, Zoia Muresan
Submitted 27 September 2010  |  Permalink Posted 27 September 2010
  I recommend this paper

This interesting paper from Hui Zheng’s lab reminds us that there is still much to learn about the normal function of the amyloid-β precursor protein (APP). Of course, it also reminds us that there is so little that we know for sure about what APP normally does. It should also remind us that the pathology in Alzheimer disease could come, at least in part, from the loss of function of APP. Finally, this paper reminds us that the APP fragments, generated by secretase cleavage in multiple cellular compartments, have functions of their own. This paper clearly shows that the fragments (in this case, sAPPβ) and full-length APP have non-overlapping functions. Moreover, the paper shows that APP and the fragments can have different functions during development and in the adult organism.

This paper does not address the problem of where the sAPPβ is normally generated, nor does it address how it is transported to the cell periphery, where it is eventually secreted. As we recently showed, all APP polypeptides, typically derived through secretase cleavage, are incorporated into transport...  Read more

  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad